Where Will Your Drug Be in 10 Years?
We can help it get there. TD2 partners with innovative biotech and pharma companies to move their oncology medicines to the market, and faster. With start-to-finish support at every moment of your drug’s journey, together we can bring cancer treatments to patients as quickly as possible.
Fast-track your research with an integrated and diverse suite of preclinical tools, from more than 300 personalized models to provide strong experimental support for your strategy to bioanalytical and ADME support services.+
Find trial-ready patients, even for rare diseases, with a real-time searchable database of millions of cancer patients in community oncology practices.+
From pre-IND evaluations through filing and maintenance support, we’ll help you along the path to approval and beyond—including strategy, meetings, paperwork and everything in between.+
“Development of new medicines requires both the best possible preclinical and clinical science. It also demands working with a great sense of urgency. The TD2 team provides innovative solutions that give new medicines the best chance to work for patients with cancer. With expert capabilities that support early discovery, pharmacokinetics, regulatory affairs and clinical development through Phase II, TD2 represents a comprehensive solution for oncology-focused companies.”
Daniel D. Von Hoff, MD, FACP, Chief Development Officer - TD2
“TD2 has a rich scientific heritage and has successfully identified, translated and applied -omics driven outcomes to speed the development of new oncology medicines, and to identify those cancer patients most likely to have clinical benefit from these new drugs.”
Jeffrey Trent, PhD, FACMG, President and Research Director - Translational Genomics Research Institute (TGen)
First cancer patient receives dose of super-enhancer inhibitor GZ17-6.02, an advanced cancer drug from Genzada Pharmaceuticals,at HonorHealth Research Institute Sterling, Kan. (March 20, 2019) Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first...
It’s no secret that conventional clinical trial design leaves ample room for improvement in oncology. Just 1 in 3 clinical trials for cancer drugs successfully advances from Phase II to Phase III. Among those, only about half make...
Too often, new drugs fail during development due to poor study design and inadequate knowledge about the performance of a new drug. A large part of these mistakes take place between Phase I and Phase II. That’s why...
Get free tips, tools and resources by subscribing to the TD2 Newsletter: